Incretin hormones and type 2 diabetes

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are crucial in type 2 diabetes pathophysiology.
• The 'incretin effect' is diminished in type 2 diabetes, primarily due to impaired GIP-mediated insulin secretion.
• This reduction contributes to poor glycemic control and highlights the need for effective therapeutic strategies.

Purpose of the Study:

• To review the role of incretin hormones in type 2 diabetes.
• To discuss the therapeutic potential of incretin-based medications.
• To explore the efficacy of dual GIP/GLP-1 receptor agonists compared to GLP-1 receptor agonists.

Main Methods:

• Review of existing literature on incretin hormones and their role in type 2 diabetes.
• Analysis of clinical data for incretin-based therapies, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists like tirzepatide.
• Examination of mechanisms underlying incretin action and therapeutic effects.

Main Results:

• GLP-1 receptor agonists effectively lower glucose and body weight in type 2 diabetes.
• Dual GIP/GLP-1 receptor agonists, such as tirzepatide, demonstrate superior reductions in HbA1c and body weight compared to selective GLP-1 receptor agonists.
• Ongoing research investigates the long-term mechanisms of GIP receptor agonism for improved glycemic control and weight loss.

Conclusions:

• Incretin-based therapies represent a significant advancement in managing type 2 diabetes.
• Dual GIP/GLP-1 receptor co-agonists offer enhanced therapeutic benefits over existing treatments.
• Future research into multi-receptor agonists may yield further improvements in diabetes management and weight control.